Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).

Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.

PMID:
30284706
2.

Probable hereditary familial overlap syndrome with multiple synchronous lung tumors.

Cardona AF, Zatarain-Barrón ZL, Rubio C, Martínez S, Ruiz-Patiño A, Ricaurte L, Serna A, Barrios R, Garzón JC, Navarrete C, Balaguera A, Corrales L, Rojas L, Arrieta O.

Lung Cancer. 2018 Oct;124:279-282. doi: 10.1016/j.lungcan.2018.08.022. Epub 2018 Aug 28.

PMID:
30268473
3.

Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

Barrón F, Cardona AF, Corrales L, Ramirez-Tirado LA, Caballe-Perez E, Sanchez G, Flores-Estrada D, Zatarain-Barrón ZL, Arrieta O; Latin American Consortium for the Study of Lung Cancer (CLICaP).

J Thorac Dis. 2018 Apr;10(4):2166-2178. doi: 10.21037/jtd.2018.03.106.

4.

Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016.

López RI, Castro JL, Cedeño H, Cisneros D, Corrales L, González-Herrera I, Lima-Pérez M, Prestol R, Salinas R, Soriano-García JL, T Zavala A, Zetina LM, Zúñiga-Orlich CE.

ESMO Open. 2018 Mar 15;3(3):e000315. doi: 10.1136/esmoopen-2017-000315. eCollection 2018. Review.

5.

Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices.

Martín C, Cardona AF, Zatarain-Barrón ZL, Ruiz-Patiño A, Castillo O, Oblitas G, Corrales L, Lupinacci L, Pérez MA, Rojas L, González L, Chirinos L, Ortíz C, Lema M, Vargas C, Puparelli C, Carranza H, Otero J, Arrieta O.

Oncology. 2018;94(5):297-305. doi: 10.1159/000486862. Epub 2018 Mar 6.

PMID:
29510386
6.

Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, Martínez-Terroba E, Perurena N, de Miguel FJ, Jantus-Lewintre E, Camps C, Vicent S, Agorreta J, Montuenga LM, Pio R, Lecanda F.

Am J Respir Crit Care Med. 2018 May 1;197(9):1164-1176. doi: 10.1164/rccm.201703-0660OC.

PMID:
29327939
7.

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

Gajewski TF, Corrales L, Williams J, Horton B, Sivan A, Spranger S.

Adv Exp Med Biol. 2017;1036:19-31. doi: 10.1007/978-3-319-67577-0_2. Review.

PMID:
29275462
8.

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.

PMID:
29061829
9.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

PMID:
28620690
10.

Acetonitrile cluster solvation in a cryogenic ethane-methane-propane liquid: Implications for Titan lake chemistry.

Corrales LR, Yi TD, Trumbo SK, Shalloway D, Lunine JI, Usher DA.

J Chem Phys. 2017 Mar 14;146(10):104308. doi: 10.1063/1.4978395.

PMID:
28298101
11.

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, Raez L, Santos E, Rolfo C.

Front Med (Lausanne). 2017 Feb 28;4:13. doi: 10.3389/fmed.2017.00013. eCollection 2017. Review.

12.
13.

Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1.

Gimeno ML, Fuertes F, Barcala Tabarrozzi AE, Attorressi AI, Cucchiani R, Corrales L, Oliveira TC, Sogayar MC, Labriola L, Dewey RA, Perone MJ.

Stem Cells Transl Med. 2017 Jan;6(1):161-173. doi: 10.5966/sctm.2016-0014. Epub 2016 Aug 2.

14.

Innate immune signaling and regulation in cancer immunotherapy.

Corrales L, Matson V, Flood B, Spranger S, Gajewski TF.

Cell Res. 2017 Jan;27(1):96-108. doi: 10.1038/cr.2016.149. Epub 2016 Dec 16. Review.

15.

Innate immune mediators in cancer: between defense and resistance.

Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R.

Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464. Review.

PMID:
27782320
16.
17.

The host STING pathway at the interface of cancer and immunity.

Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892. Epub 2016 Jul 1. Review.

18.

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.

Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M, Kline J.

Cell Rep. 2016 Jun 14;15(11):2357-66. doi: 10.1016/j.celrep.2016.05.023. Epub 2016 Jun 2.

19.

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R; CLICaP.

PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016.

20.

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Immunol. 2016 Apr 1;196(7):3191-8. doi: 10.4049/jimmunol.1502538. Epub 2016 Feb 29.

21.

Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Spranger S, Sivan A, Corrales L, Gajewski TF.

Adv Immunol. 2016;130:75-93. doi: 10.1016/bs.ai.2015.12.003. Epub 2016 Jan 22.

22.

Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.

Arina A, Corrales L, Bronte V.

Semin Immunol. 2016 Feb;28(1):54-63. doi: 10.1016/j.smim.2016.01.002. Epub 2016 Feb 10. Review.

PMID:
26872631
23.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF.

Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.

24.

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.

Corrales L, Gajewski TF.

Clin Cancer Res. 2015 Nov 1;21(21):4774-9. doi: 10.1158/1078-0432.CCR-15-1362. Epub 2015 Sep 15. Review.

25.

Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.

Corrales L, Gajewski TF.

Cytokine. 2016 Jan;77:245-7. doi: 10.1016/j.cyto.2015.08.258. Epub 2015 Aug 24. No abstract available.

26.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF.

Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.

27.

Targeting the innate immune system as immunotherapy for acute myeloid leukemia.

Curran E, Corrales L, Kline J.

Front Oncol. 2015 Apr 9;5:83. doi: 10.3389/fonc.2015.00083. eCollection 2015. Review.

28.

The STING pathway and the T cell-inflamed tumor microenvironment.

Woo SR, Corrales L, Gajewski TF.

Trends Immunol. 2015 Apr;36(4):250-6. doi: 10.1016/j.it.2015.02.003. Epub 2015 Mar 7. Review.

29.

New perspectives on type I IFNs in cancer.

Gajewski TF, Corrales L.

Cytokine Growth Factor Rev. 2015 Apr;26(2):175-8. doi: 10.1016/j.cytogfr.2015.01.001. Epub 2015 Jan 7. Review.

30.

Innate immune recognition of cancer.

Woo SR, Corrales L, Gajewski TF.

Annu Rev Immunol. 2015;33:445-74. doi: 10.1146/annurev-immunol-032414-112043. Epub 2015 Jan 22. Review.

PMID:
25622193
31.

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.

Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R; CLICaP.

Lung Cancer. 2015 Feb;87(2):169-75. doi: 10.1016/j.lungcan.2014.12.009. Epub 2014 Dec 18.

PMID:
25558790
32.

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF.

Immunity. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5. Erratum in: Immunity. 2015 Jan 20;42(1):199.

33.

Support for smoke-free multi-unit housing policies among racially and ethnically diverse, low-income seniors in South Florida.

Cook NJ, Hollar L, Chavez S, Quinn DL, Phillips T, DeLucca M, Corrales L.

J Cross Cult Gerontol. 2014 Dec;29(4):405-15. doi: 10.1007/s10823-014-9247-4.

34.

Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration.

Calleja P, Espuelas S, Corrales L, Pio R, Irache JM.

Nanomedicine (Lond). 2014 Jul;9(14):2109-21. doi: 10.2217/nnm.13.199. Epub 2014 Jan 28.

35.

The role of complement in tumor growth.

Pio R, Corrales L, Lambris JD.

Adv Exp Med Biol. 2014;772:229-62. doi: 10.1007/978-1-4614-5915-6_11. Review.

36.

Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Ajona D, Pajares MJ, Corrales L, Perez-Gracia JL, Agorreta J, Lozano MD, Torre W, Massion PP, de-Torres JP, Jantus-Lewintre E, Camps C, Zulueta JJ, Montuenga LM, Pio R.

J Natl Cancer Inst. 2013 Sep 18;105(18):1385-93. doi: 10.1093/jnci/djt205. Epub 2013 Aug 12.

37.

The Hanes-Woolf linear QUESP method improves the measurements of fast chemical exchange rates with CEST MRI.

Randtke EA, Chen LQ, Corrales LR, Pagel MD.

Magn Reson Med. 2014 Apr;71(4):1603-12. doi: 10.1002/mrm.24792. Epub 2013 Jun 18.

38.

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.

Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S.

Curr Opin Immunol. 2013 Apr;25(2):268-76. doi: 10.1016/j.coi.2013.02.009. Epub 2013 Apr 8. Review.

PMID:
23579075
39.

[Mucopenetrating nanoparticles: vehicles for the oral administration of paclitaxel].

Zabaleta V, Calleja P, Espuelas S, Corrales L, Pío R, Agüeros M, Irache JM.

Ann Pharm Fr. 2013 Mar;71(2):109-18. doi: 10.1016/j.pharma.2012.12.005. Epub 2013 Feb 27. French.

PMID:
23537412
40.

Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R.

J Immunol. 2012 Nov 1;189(9):4674-83. doi: 10.4049/jimmunol.1201654. Epub 2012 Oct 1.

41.

Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade.

Okroj M, Holmquist E, Sjölander J, Corrales L, Saxne T, Wisniewski HG, Blom AM.

J Biol Chem. 2012 Jun 8;287(24):20100-10. doi: 10.1074/jbc.M111.324913. Epub 2012 Apr 23.

42.

Novel analysis of cation solvation using a graph theoretic approach.

Mooney BL, Corrales LR, Clark AE.

J Phys Chem B. 2012 Apr 12;116(14):4263-75. doi: 10.1021/jp300193j. Epub 2012 Mar 28.

PMID:
22417120
43.

MoleculaRnetworks: an integrated graph theoretic and data mining tool to explore solvent organization in molecular simulation.

Mooney BL, Corrales LR, Clark AE.

J Comput Chem. 2012 Mar 30;33(8):853-60. doi: 10.1002/jcc.22917. Epub 2012 Jan 25.

PMID:
22278855
44.

[Identification of marine and coastal biodiversity conservation priorities in Costa Rica].

Alvarado JJ, Herrera B, Corrales L, Asch J, Paaby P.

Rev Biol Trop. 2011 Jun;59(2):829-42. Spanish.

PMID:
21721241
45.

Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer.

Subramanian J, Corrales L, Soulieres D, Morgensztern D, Govindan R.

J Thorac Oncol. 2011 Feb;6(2):399-403. doi: 10.1097/JTO.0b013e318200f972.

46.

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer.

Pio R, Garcia J, Corrales L, Ajona D, Fleischhacker M, Pajares MJ, Cardenal F, Seijo L, Zulueta JJ, Nadal E, Witt C, Lozano MD, Schmidt B, Montuenga LM.

Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2665-72. doi: 10.1158/1055-9965.EPI-10-0467. Epub 2010 Aug 27.

47.

Femoral nailing during serum bicarbonate-defined hypo-perfusion predicts pulmonary organ dysfunction in multi-system trauma patients.

Morshed S, Corrales LA, Lin K, Miclau T.

Injury. 2011 Jul;42(7):643-9. doi: 10.1016/j.injury.2010.07.244. Epub 2010 Aug 3.

PMID:
20678765
48.

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, Pio R.

Mol Cancer. 2010 Jun 7;9:139. doi: 10.1186/1476-4598-9-139.

49.

Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment.

Martínez-García E, Irigoyen M, González-Moreno O, Corrales L, Teijeira A, Salvo E, Rouzaut A.

Toxicol Sci. 2010 Aug;116(2):467-76. doi: 10.1093/toxsci/kfq138. Epub 2010 May 10.

50.

Intrinsic electronic transitions of the absorption spectrum of (OPy)2Ti(TAP)2: implications toward photostructural modifications.

De Silva CR, Musgraves JD, Schneider Z, Potter BG Jr, Boyle TJ, Simmons-Potter K, Corrales LR.

J Phys Chem A. 2009 May 14;113(19):5598-601. doi: 10.1021/jp9016008.

PMID:
19371052

Supplemental Content

Loading ...
Support Center